Application of an in vitro digestion model to study the metabolic profile changes of an herbal extract combination by UHPLC-HRMS.

Autor: Thumann TA; Institute of Pharmaceutical Sciences, Department of Pharmacognosy, University of Graz, Universitätsplatz 4, 8010 Graz, Austria; BioTechMed, Mozartgasse 12, 8010 Graz, Austria., Pferschy-Wenzig EM; Institute of Pharmaceutical Sciences, Department of Pharmacognosy, University of Graz, Universitätsplatz 4, 8010 Graz, Austria; BioTechMed, Mozartgasse 12, 8010 Graz, Austria., Aziz-Kalbhenn H; Steigerwald Arzneimittelwerk GmbH, Bayer Consumer Health, Havelstraße 5, 64295 Darmstadt, Germany., Ammar RM; Steigerwald Arzneimittelwerk GmbH, Bayer Consumer Health, Havelstraße 5, 64295 Darmstadt, Germany; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Kafrelsheikh University, 33511 Kafrelsheikh; Egypt., Rabini S; Steigerwald Arzneimittelwerk GmbH, Bayer Consumer Health, Havelstraße 5, 64295 Darmstadt, Germany., Moissl-Eichinger C; BioTechMed, Mozartgasse 12, 8010 Graz, Austria; Diagnostic and Research Institute of Hygiene, Microbiology and Environmental Medicine, Medical University of Graz, Neue Stiftingtalstraße 6, 8010 Graz, Austria., Bauer R; Institute of Pharmaceutical Sciences, Department of Pharmacognosy, University of Graz, Universitätsplatz 4, 8010 Graz, Austria; BioTechMed, Mozartgasse 12, 8010 Graz, Austria. Electronic address: rudolf.bauer@uni-graz.at.
Jazyk: angličtina
Zdroj: Phytomedicine : international journal of phytotherapy and phytopharmacology [Phytomedicine] 2020 Jun; Vol. 71, pp. 153221. Date of Electronic Publication: 2020 May 01.
DOI: 10.1016/j.phymed.2020.153221
Abstrakt: Background: STW 5 is a fixed herbal combination containing extracts from nine medicinal plants: bitter candytuft, greater celandine, garden angelica roots, lemon balm leaves, peppermint leaves, caraway fruits, licorice roots, chamomile flowers, and milk thistle fruit. STW 5 is a clinically proven treatment for functional dyspepsia and irritable bowel syndrome.
Purpose: Using a static in vitro method, we simulated oral, gastric, and small intestinal digestion and analyzed the metabolic profile changes by UHPLC-HRMS to determine the impact of oro-gastro-intestinal digestion on STW 5 constituents.
Study Design and Methods: STW 5 was incubated according to the InfoGest consensus method. Samples of each digestive phase were analyzed by UHPLC-HRMS in ESI positive and negative modes. After data processing, background subtraction, and normalization, the peak areas of detectable compounds were compared to untreated reference samples and recovery ratios were calculated to monitor the metabolic profile of STW 5 during simulated digestion.
Results: Although the levels of some constituents were reduced, we did not observe complete degradation of any of the constituents of STW 5 upon in vitro digestion. We did not detect any new metabolites beyond increased levels of caffeic acid and liquiritigenin due to degradation of progenitor compounds. Changes observed in intestinal bioaccessibility ratios were mainly a result of isomerization, hydrolysis, protein binding, and low water solubility.
Conclusion: The majority of STW 5 constituents are stable towards simulated in vitro digestion and can reach the colon to interact with gut microbiota if they remain unabsorbed in the upper intestinal tract.
Competing Interests: Declaration of Competing Interest The PhD position of Timo A. Thumann was funded by Bayer Consumer Health (Havelstraße 5, 64295 Darmstadt, Germany). Heba Aziz-Kalbhenn, Ramy M. Ammar, and Sabine Rabini are fully employed by Bayer Consumer Health (Havelstraße 5, 64295 Darmstadt, Germany). All other authors report no declarations of interest.
(Copyright © 2020 The Author(s). Published by Elsevier GmbH.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: